Excelra’s COVID-19 Resource Hub
COVID-19 Biomarker Database
This ‘Open-Access’ resource is excerpted from our GOBIOM platform – the world’s largest biomarker intelligence database. The database is a compilation of manually curated biomarkers from published clinical trials, evaluating potential drugs or biologics for the treatment of SARS-CoV-2.
The database additionally includes information on FDA-NIH recommended BEST (Biomarkers, EndpointS and other Tools) classification of biomarkers, supported with direct links to the referenced literature. The database is updated regularly with COVID-19 relevant clinical trials published in clinicaltrials.gov.
COVID-19 Drug Repurposing Database
This ‘Open-Access’ database is a synoptic compilation of ‘Approved’ small molecules and biologics, which can rapidly enter either Phase 2 or 3, or may even be used directly in clinical settings against COVID-19.
The database additionally includes information on promising drug candidates that are in various ‘clinical, pre-clinical and experimental’ stages of drug discovery and development. Supported with referenced literature, we provide mechanistic insights into SARS-CoV-2 biology and disease pathogenesis.